Moxie Clinical

Moxie Clinical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Moxie Clinical is a San Francisco-based, private CRO founded in 2018, targeting the specific challenges of emerging biotech and MedTech sponsors. Its business model is service-based, offering flexible support from strategic consulting to full-scale trial management, enhanced by a proprietary technology platform utilizing AI and decentralized trial tools. The company positions itself as a strategic, integrated partner rather than just a service vendor, aiming to reduce trial errors, timelines, and costs for its clients in therapeutic areas like neurology, ophthalmology, and cardiovascular disease.

NeurologyOphthalmologyCardiovascular

Technology Platform

Integrated platform utilizing AI-powered analytics for trial optimization and monitoring, decentralized trial (DCT) capabilities for patient-centric studies, and risk-based monitoring (RBM) methodologies.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The growing trend of outsourcing by resource-constrained emerging biotech/MedTech companies and the industry-wide shift towards decentralized trials and AI-driven analytics create a substantial market.
Moxie's boutique, tech-integrated model is well-positioned to capture this demand.

Risk Factors

Faces intense competition from large global CROs and other boutiques.
Revenue is susceptible to downturns in biotech funding cycles.
Success depends on flawless execution of complex trials and the ability to scale its high-touch service model effectively.

Competitive Landscape

Competes against large, full-service CROs (e.g., IQVIA, Parexel, PPD) and a crowded field of boutique CROs. Differentiates through its stated 'sponsor-born' perspective, integrated partnership model, and a focused value proposition combining boutique service with advanced trial technology.